In the first half of 2025, Pfizer's oncology segment contributed over 25% of its total revenues, demonstrating a significant upward trend. Notably, oncology revenues grew by 9%, driven by several key ...

HCW Biologics shares logged their best session in over three months on Monday after the firm revealed progress with a new ...

HCW Biologics Inc. (NASDAQ: HCWB) shares were up Monday after the company announced a breakthrough in developing second-generation pembrolizumab-based immunotherapies for solid tumors.

Merck (MRK) is set to present new clinical trial data at the European Society of Cardiology Congress 2025, emphasizing advancements in cardiovascular disease management. Over the last quarter, Merck's ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.

HCW Biologics shares jump after unveiling TRBC-based fusion therapy that enhances immune response and shows strong ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...